Ballicules.com

Roflumilast

DALIRESP

Pronunciation: roe-FLOO-mi-last (DA-li-resp)

Roflumilast ballicule: receptor binding, kinetics and half-life diagram
Mechanism of action: Roflumilast ballicule

What it isSelective PDE4 inhibitor with anti-inflammatory action; severe COPD with chronic bronchitis and exacerbations.

Why this oneIt reduces exacerbations in the chronic bronchitis phenotype, which bronchodilators alone do not.

What limits itWeight loss, diarrhea and psychiatric effects limit tolerability. It is not a bronchodilator and does nothing acutely.

Roflumilast molecular structure (skeletal formula)
Molecular structure: Roflumilast

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Reduce risk of COPD exacerbationsAdults250 mcg QD x 4 weeks (to improve tolerability), then 500 mcg QD500 mcg QD500 mcg QD

Renal No dosage adjustment needed

Hepatic Mild (Child-Pugh A): weigh risk-benefit; contraindicated in moderate-severe (Child-Pugh B or C)

250 mcg is a starting/tolerability dose only and is not the effective (therapeutic) dose

Instructions

Available strengths

Contraindications

Cautions

Adverse reactions

Pregnancy No human data; should not be used during labor and delivery; animal adverse effects at high multiples of MRHD.

Lactation Excretion into human milk probable; should not be used while nursing.

Cost

Roflumilast (DALIRESP)
What pharmacies pay · NADAC 9/30/26
Strength#/mogeneric $/moCostPlus
250 mcgtab30 qd$59.44offered
500 mcgtab30 qd$9.34offered

Generic entry2018

NO BOXED WARNINGS

Principal riskWeight loss and psychiatric effects

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger2 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk1 / 4

Legacy pregnancy categoryC

Defining liabilityTremor, tachycardia or anticholinergic effects; excessive beta-agonist exposure can cause hypokalemia and arrhythmia.

Open Roflumilast in the interactive console ↗